David Swoboda, MD, Talks MDS Highlights at ASH 2023

By David Swoboda, MD - Last Updated: January 3, 2024

Dr. Swoboda, Director of Leukemia at Tampa General Hospital in Florida, talks highlights on myelodysplastic syndromes (MDS) from the 65th American Society of Hematology Annual Meeting & Exposition.

Advertisement

“We’ve had a great year in MDS with two pivotal phase III studies presented at ASCO, the first being the COMMANDS study with luspatercept,” he said. “This was a frontline study [that was] extremely practice-changing for a lot of clinicians and researchers.”

He added the other trial was the phase III IMerge trial, the randomized, double-blind, placebo-controlled study evaluated imetelstat in patients with heavily transfusion dependent non-del(5q) lower-risk MDS who relapsed or were refractory to erythropoiesis stimulating agents.

Post Tags:ASHMDS23
Advertisement
Advertisement
Advertisement